Oncology

Antibody Drug Conjugate and Big Pharmaceutical Companies Boom Antibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments show success, more companies are looking to produce these drugs. Although antibody-drug conjugates show promise in the development of effective cancer therapies, there are still a variety of challenges involved in enabling the safe manufacture of these hazardous drugs. ADC’s continues to gain popularity but the market is in infant stage with only 3 drugs approved by U.S. FDA. Mylotarg from Wyeth (now Pfizer) was the 1st drug approved for the treatment of acute myeloid leuk...